Contact
Daniel Levine
Principal
(510) 280-5405
danny@levinemediagroup.com
December 3, 2018
Notable Labs Collaborator at ASH Shows Company’s Platform Predicts Ex Vivo Drug Response in Myeloid Neoplasms
SAN DIEGO and FOSTER CITY, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Notable Labs, Inc., a mission-driven company aiming to transform the way cancer is treated, announced today that the Company and its collaborators will present results of their research at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 1-4 in San Diego.
July 11, 2018
Collaboration Among Foundations
Levine Media Group's Daniel Levine Moderates this Global Genes' webinar about collaborations between rare disease foundations and how to make the most of them. Today, advocate and patients are becoming drivers in the rare disease community, but it will be hard to make strides without coming together and working towards the same goal. Join us for this RARE Webinar to discuss how foundations can break down any barriers and work together to achieve foundation and rare disease goals. Gain advice and learn best practices from those who have already taken the first steps in cross foundation collaboration. You can view a replay of the webinar here.
June 28, 2018
Amfora Unveils Broad Initiative to Develop Crops with Enhanced Protein Content for Food and Feed
SAN FRANCISCO, June 28, 2018 (GLOBE NEWSWIRE) -- Amfora Inc., a biotechnology company committed to improving the nutritional content of food and feed crops, today unveiled a major new program to develop crops with enhanced protein.
May 14, 2018
Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
SAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said investigators dosed the first patient in its Phase 1 trial of PolyPEPI™ 1018, the company’s investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).
April 11, 2018
Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer
SAN FRANCISCO and LONDON, April 11, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said it had successfully activated its clinical trial site at the Mayo Clinic in Rochester, Minnesota for its Phase 1 trial of PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).
April 3, 2018
Treos Bio Names Gábor Illés as Its Chief Financial Officer
SAN FRANCISCO and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today named Gábor Illés as its Chief Financial Officer. Mr. Illés has served as a non-executive investor director of Treos since the company’s inception.
February 16, 2018
Why Africa Should Take a Cue from China
Proxenia Venture Partners CEO Dr. Menghis Bairu discusses what Africa can learn from China about building a knowledge-based economy in this opinion piece published in African Leadership Magazine
January 24, 2018
Treos Bio Announces FDA Approval of IND of Its First PolyPEPI™ Precision Cancer Vaccine for Metastatic Colorectal Cancer
SAN FRANCISCO and LONDON, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) Application for PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC), and has provided authorization to proceed with the Phase 1 study in mCRC patients.
January 9, 2018
Biotech Showcase: Drivers of Innovation: Evolving Models in Rare Disease Drug Development
Levine Media Group's Daniel Levine moderates this panel of executives from leading rare disease drug development comapanies at the Biotech Showcase in San Francisco. You can view a replay of the panel discussion here.